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Abstract
Background: We present the design, methods and population characteristics of a large community trial that
assessed the efficacy of a weekly supplement containing vitamin A or beta-carotene, at recommended dietary
levels, in reducing maternal mortality from early gestation through 12 weeks postpartum. We identify challenges
faced and report solutions in implementing an intervention trial under low-resource, rural conditions, including the
importance of population choice in promoting generalizability, maintaining rigorous data quality control to reduce
inter- and intra- worker variation, and optimizing efficiencies in information and resources flow from and to the
field.
Methods: This trial was a double-masked, cluster-randomized, dual intervention, placebo-controlled trial in a
contiguous rural area of ~435 sq km with a population of ~650,000 in Gaibandha and Rangpur Districts of
Northwestern Bangladesh. Approximately 120,000 married women of reproductive age underwent 5-weekly home
surveillance, of whom ~60,000 were detected as pregnant, enrolled into the trial and gave birth to ~44,000 live-
born infants. Upon enrollment, at ~ 9 weeks’ gestation, pregnant women received a weekly oral supplement
containing vitamin A (7000 ug retinol equivalents (RE)), beta-carotene (42 mg, or ~7000 ug RE) or a placebo
through 12 weeks postpartum, according to prior randomized allocation of their cluster of residence. Systems
described include enlistment and 5-weekly home surveillance for pregnancy based on menstrual history and urine
testing, weekly supervised supplementation, periodic risk factor interviews, maternal and infant vital outcome
monitoring, birth defect surveillance and clinical/biochemical substudies.
Results: The primary outcome was pregnancy-related mortality assessed for 3 months following parturition.
Secondary outcomes included fetal loss due to miscarriage or stillbirth, infant mortality under three months of age,
maternal obstetric and infectious morbidity, infant infectious morbidity, maternal and infant micronutrient status,
fetal and infant growth and prematurity, external birth defects and postnatal infant growth to 3 months of age.
Conclusion: Aspects of study site selection and its “resonance” with national and rural qualities of Bangladesh, the
trial’s design, methods and allocation group comparability achieved by randomization, field procedures and
innovative approaches to solving challenges in trial conduct are described and discussed. This trial is registered
with http://Clinicaltrials.gov as protocol NCT00198822.
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Community trials, incorporating principles and methods
of a randomized, controlled design, represent a “gold stan-
dard” methodology for generating evidence on efficacy or
effectiveness of health and nutrition interventions. In low-
income countries, where resources may be minimal, infra-
structure undeveloped and political stability uncertain,
numerous challenges exist to their design and conduct. A
study site should reflect, to the degrees possible, numerous
characteristics of the population for whom results are to
be interpreted, qualities that can promote generalizability
of future findings. For trials seeking to measure impact on
rare events, such as mortality, study size, reflected in sam-
ple size and numbers of data handling staff, and duration,
which may extend for years, present challenges to main-
taining data accuracy and reliability. Large and long trials
may be subject to substantial size- and time-dependent
biases that can occur with procedural drift, in the absence
of adequate, organized, supervised and enforced quality
control. Beyond meeting technical demands, scientific
rigor and ethical obligations, operational success of a large
community trial requires a well developed, multifaceted
and adequately funded organization, supportive political
and social relationships, and sensitivity toward minimizing
distortions to the local economy and culture.
Over the past decade, large field trials have been con-
ducted to evaluate the efficacy of antenatal micronutri-
ent supplement use on maternal and infant mortality, in
Southern Asia [1,2] and Africa [3-6], helping to establish
levels of impact of practical interventions under diverse
environmental, nutrition and disease conditions. While
informative, there remains a general lack of substantive
descriptions and critical treatises on design, site, and
methodological and organizational requirements for
implementing large, community based nutrition trials.
This paper seeks to help fill this gap by describing
aspects of design, study site selection, technical chal-
lenges encountered and solutions developed to maintain
quality control and optimize efficiencies during the con-
duct of a large (60,000 pregnancy/44,000 infant), long
(6.5 year), cluster-randomized, controlled trial in rural
northern Bangladesh that evaluated the prophylactic
efficacy of maternal vitamin A (VA) supplementation
during and after pregnancy in reducing maternal, fetal
and infant mortality. The trial was carried out in the
rural Districts of Gaibandha and Rangpur, amidst a
region historically affected by high maternal mortality,
VA deficiency and poor health care [7].
Methods
Aims of the study
The study, called “JiVitA-1” represents the first large
community trial undertaken by the JiVitA Health and
Nutrition Research Project (JiVitA) from 2001 to 2007.
The primary aim of JiVitA-1 was to establish the efficacy
o faw e e k l yo r a ld o s eo fV Ao rb e t a - c a r o t e n e ,a d m i n i s -
tered from early pregnancy through three months post-
partum, at concentrations that approximated a recom-
mended dietary allowance, in reducing all-cause mortal-
ity of women related to pregnancy by at least 35%.
Secondary aims included determining the impact of
maternal VA or beta-carotene supplementation during
pregnancy and postpartum periods on fetal loss due to
miscarriage or stillbirth, infant mortality under three
months of age, maternal obstetric and infectious mor-
bidity, infant infectious morbidity, maternal and infant
micronutrient status, fetal and infant growth and prema-
turity, gross external birth defects and infant growth to
3 months of age.
Study Site Selection
In order to support a large, cluster-randomized trial
intended to inform national policy considerations, it was
critical that the study site broadly reflect vital, health and
nutritional risks and exposures of the national rural
population, a quality of research sites we refer to as
“resonance”. The process of site selection involved several
months of site visits throughout the country and abstrac-
tion of disaggregated national data from multiple sources
on rural infrastructure, health care, agriculture and
demography. An area comprising 19 rural unions in the
northwest Districts of Gaibandha and Rangpur became
the preferred site, based on survey reports of maternal
night blindness, reflecting VA deficiency, remoteness and
rural quality (e.g., mostly villages surrounded by rice
fields, linked by unpaved roads), area size (~435 sq km)
and contiguity, population density (~1000 per sq km) [7],
agrarian nature (e.g., seasonality and crop mix, weekly
market network), and a receptive political culture and
administrative system,. These qualities were further sup-
ported by a relatively accessible, urban center (Rangpur
City) lying within a few hours of the field site that could
support data management and logistics requirements (e.
g., electrical supply, telecommunications, trunk road
access, basic residence facilities) (Figure 1) [8]. The area
appeared to represent, broadly, the ~35
th percentile of
economic and quality of life in rural Bangladesh, based
on comparative reports of food production, flood risks
and other environmental hazards, maternal and child diet
and nutritional and health status and health care utiliza-
tion [7], reflecting resonance with the national rural con-
text of Bangladesh, as detailed in Table 1[9,10].
Field Organization
The trial required a rural addressing and surveillance
system capable of identifying, enrolling and tracking
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December 2000, over 120,000 households in the study
area were located and placed on digitized land-allocation
maps as part of a JiVitA Geographic Information System
(GIS), described elsewhere [11]. The study area was seg-
regated into 596 units of both work management and
randomization, called “sectors”, each of ~250 households
in size and covered by a single resident field worker
(Field Supplement Distributor, or FD). A team of 10-12
FD’s was supervised by a single Team Leader (TL), also
a local resident and based in a local office. Four leaders
of adjacent team areas (~40-44 sectors) were supervised
by a single “Area Coordinator (AC)”, also residing in the
local area. The 12 coordinated areas were overseen by
two field managers under direct administrative and
technical and administrative direction of a senior man-
agement team and study investigators.
Study Area Census
In July 2001, a study census enumerated 102,771 women
eligible to participate in the JiVitA-1 trial. All consenting
women of reproductive age (13-44 years), married and
living with their husbands, not sterilized or menopausal
or whose husbands were not sterilized, were eligible to
be enlisted into a 5-weekly, home-based, pregnancy sur-
veillance system. Pregnant or post partum, lactationally
amenorrheic women were placed on a ‘waiting list’,a n d
only became eligible for pregnancy surveillance once
their menses resumed. Women entering the study area
within 4 months of marriage were also eligible to join
the cohort under pregnancy surveillance. Eligible preg-
nant women were enrolled over a period that began in
August 2001 and ended in October 2006.
Intervention
Each woman under active surveillance was visited once
every 5 weeks by the FD assigned to their sector.
Women were asked about their menses in the past 30
days; if amenstrual, they were offered a urine-based
hCG pregnancy test (Orchid Biomedical Systems, Goa,
India). The 5-week interval was chosen as a standard
length of time (with biologic variability) between preg-
nancy surveillance visits to allow normal menarcheal
cycles to occur (28 ± 4 days)[12]. A shorter interval
Figure 1 The JiVitA Research Project setting, a population dense (~1000 persons per sq km), contiguous rural area of ~ 450 sq km at
30 m above mean sea level, west of the confluence of the Teesta and Jamuna rivers of Northwest Bangladesh.
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Bangladesh as a whole (column 1), and only Rural Bangladesh (column 2)
Bangladesh -
Overall
Rural
Bangladesh
Gaibandha Difference between Rural Bangladesh and
Gaibandha
(1) (2) (3) (2)-(3)
%% % %
Women of Reproductive Age
Age, years
15-19 21.9 21.8 20.3 1.5
20-24 18.1 18.1 19.9 -1.8
25-29 16.0 15.9 15.8 0.1
30-34 13.4 13.6 13.4 0.2
35-39 12.7 12.5 13.3 -0.8
40-44 9.5 9.5 10.0 -0.5
45-49 8.5 8.8 7.2 1.6
Education
None 34.1 37.6 41.1 -3.5
Primary incomplete 13.8 15.5 12.3 3.2
Primary complete 11.9 12.5 9.0 3.5
Secondary incomplete 27.1 26.8 25.2 1.6
Secondary complete or higher 12.8 7.3 11.7 -4.4
Non-standard curriculum 0.4 0.4 0.7 -0.3
Household characteristics
Floor construction
Earth/sand 78.2 90.4 84.4 6.0
Palm/bamboo/wood 1.2 1.2 0.0 1.2
Cement 20.0 8.3 15.6 -7.3
Roof construction
Thatch/leaf 6.8 7.8 4.7 3.1
Palm/bamboo 0.5 0.5 0.5 0.0
Metal/Tin 83.4 87.5 91.9 -4.4
Cement 7.5 2.2 2.9 -0.7
Wall construction
Cane/palm/leaf/jute sticks 8.5 11.0 12.7 -1.7
Dirt/mud 15.5 17.9 15.7 2.2
Bamboo/Bamboo with mud 16.8 16.9 10.6 6.3
Tin sheet 34.9 39.2 43.0 -3.8
Bricks 21.2 12.0 16.7 -4.7
Household assets
Electricity 50.5 39.3 37.5 1.8
Radio 30.2 29.3 27.7 1.6
Television 34.6 24.8 25.5 -0.7
Mobile phone 25.2 18.4 15.1 3.3
Watch 72.9 69.5 58.9 10.6
Bicycle 27.7 28.6 30.3 -1.7
Motorcycle or scooter 3.6 2.4 3.9 -1.5
Rickshaw van 5.7 5.5 6.5 -1.0
Government Health Services
Nutrition Program Coverage
Vitamin A supplementation -
Children
1
89.2 88.3 90.8 -2.5
Postpartum Vitamin A
supplementation
2
17.2 15.8 18.0 -2.2
Child and Maternal Vaccination
3
BCG 97.0 96.7 98.4 -1.7
DPT (1
st Dose) 96.6 96.2 98.4 -2.2
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gladesh as a whole (column 1), and only Rural Bangladesh (column 2) (Continued)
Polio (1
st Dose) 99.1 99.0 100.0 1.0
Measles 87.5 87.2 93.7 -6.5
Maternal tetanus toxoid (TT)
4 89.6 88.9 85.7 3.2
Environmental characteristics
Source of drinking water
Piped into dwelling or common
area
6.6 0.3 2.0 -1.7
Tubewell/borehole 88.7 95.9 94.8 1.1
Sanitation
Piped sewer system 2.9 0.2 0.3 -0.1
Septic tank system 13.2 7.2 15.7 -8.5
Closed-slab pit latrine (Sealed) 23.1 24.5 23.9 0.6
Open pit/Hanging Toilet 52.1 58.3 35.5 22.8
No facilities or bush or field 7.5 9.2 23.3 -14.1
Use of improved sanitation
5 39.2 31.9 39.9 -8.0
Reproductive Health
Antenatal Care Provider
Medical doctor 37.1 31.1 26.3 4.8
Nurse/midwife 10.6 10.1 12.0 -1.9
Community health worker 4.6 5.1 5.3 -0.2
No ANC received 43.8 49.2 48.9 0.3
Assistance at delivery
Medical doctor 15.5 10.6 7.5 3.1
Nurse/midwife 4.6 3.4 6.0 -2.6
TBA 66.0 71.1 48.1 23.0
Relative/Friend 11.2 12.3 33.1 -20.8
Place of delivery
Home 82.7 88.2 89.2 1.0
Delivery in health facility
6 16.0 10.7 9.0 1.7
Education
School attendance, by Sex
Primary school attendance (Male) 78.9 79.0 73.4 5.6
Primary school attendance (Female) 83.7 84.2 75.5 8.7
Secondary school attendance (Male) 36.2 33.6 38.3 -4.7
Secondary school attendance
(Female)
41.4 39.4 36.3 3.1
Adult (15-24 years) literacy
Female 69.9 67.6 62.8 4.8
Early marriage
Married before age 15
7 33.1 36.2 40.0 -3.8
Married before age 18
8 74.0 78.4 79.7 -1.3
Married women, aged 15-19 years 41.9 46.1 51.3 -5.2
Public-access data analyzed from the 2006 Multiple Indicator Cluster Survey (MICS), conducted by the Bangladesh Bureau of Statistics (BBS) between June and
October 2006, sponsored by UNICEF (16). A total 62,463 households (1,950 clusters) were surveyed, where 1,280 clusters were from rural areas and 38 were from
Gaibandha (16). (Some category totals do not add to 100% as rows may have been omitted for brevity, or lack of information.)
1Children of age 9-59 months who received vitamin A supplementation in the last six months prior to the survey interview.
2Mothers aged 15-49 years with a birth in the two years preceding the survey who received high-dose vitamin A supplementation before the infant was 8 weeks
old.
3Children aged 12-23 months with proof of current vaccination against childhood disease.
4TT: Mothers with live births in one year preceding the survey who were given at least two doses of tetanus toxoid vaccine within the appropriate interval prior
to giving birth.
5Improved sanitation facilities are: flush to piped sewer system, flush to septic tank, flush to pit latrine and pit latrine with slab.
6Health facility: public sector and private sector health facilities.
7Numerator: number of women that were first married by the exact age of 15 and denominator: total number of women aged 15-49 years.
8Numerator: number
of women that were first married by the exact age of 18.2 and denominator: total number of women aged 15-49 years.
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before menstrual onset, resulting in unnecessary preg-
nancy testing. Following a positive result, consenting
pregnant women were administered a coded supplement
each week, through 3 months postpartum. Ideally, sup-
plements were taken under staff supervision, but when
directly observed supplementation was not possible for a
particular woman in a given week, a distinct code was
recorded in the weekly dosing log. As the intervention
was cluster-randomized, all enrolled pregnant women in
a given sector received a weekly capsule containing one
of the following masked ingredients: (1) Placebo (con-
sisting of soybean oil with a small amount of vitamin E
as an antioxidant), (2) VA (consisting of 7000 ug retinol
equivalents, or 23,300 IU, of VA palmitate in soybean
oil with a small amount of vitamin E as an antioxidant),
or (3) Beta-carotene (consisting of 42 mg of all-trans
beta-carotene, equivalent to 7000 ug of retinol equiva-
lents, assuming a 6:1 conversion ratio). (See Figure 2).
Outcomes
The primary outcome of interest was all-cause preg-
nancy-related mortality defined as death from any cause
during pregnancy through 12-weeks post-pregnancy
outcome (including early pregnancy losses such as mis-
carriages, induced and spontaneous abortions and still-
births) per 100,000 pregnancies. Maternal vital status
was assessed weekly as women continued to be visited
by female supplement distributors through 3 months
post partum. Family members of deceased women were
visited by a trained research physician, who conducted a
“Maternal Verbal Autopsy” interview.
Fetal loss due to miscarriage or stillbirth was defined
as a pregnancy that ended without a live birth before 28
weeks or ≥28 gestation, respectively. Induced abortions,
or ‘menstrual regulations’, were also registered as out-
comes. Pregnancy losses were assessed weekly during
supplementation visits to the home and confirmed with
ap r e g n a n c yt e s tf o l l o w i n gt h er e p o r t e dl o s s .W o m e n
who experienced a pregnancy loss were visited within a
week or two of the reported loss by a study interviewer
who conducted a “Miscarriage/Stillbirth” interview.
Perinatal, neonatal and three-month mortality were
defined as (a) stillbirth plus deaths within the first 7
days of birth, (b) infant deaths occurring within 28 days
of a live birth, and (c) infant deaths occurring with the
first 12 weeks of life, all per 1000 live births. Infant vital
status was assessed weekly through 12 weeks of age by a
study interviewer, and monthly thereafter. Parents of
deceased infants were visited by a trained interviewer
who conducted an “Infant Verbal Autopsy” interview.
Maternal obstetric and infectious morbidity was
assessed by a structured interview conducted 3 months
after pregnancy outcome and based on self-reported his-
tory of symptoms that occurred in the seven days before
or after the pregnancy outcome, and in the 3 month
period after the outcome. Any woman reporting night
blindness in early pregnancy was given a “Night
Figure 2 Basic trial design of JiVitA-1 and pregnancy identification.
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described locally available beta-carotene and vitamin-A
rich foods for consumption. At ~28 weeks of gestation,
night blindness was again assessed by interview and sus-
pected cases were offered the standard WHO regimen
for treatment of night blindness in pregnancy (25,000
IU VA weekly for four weeks at a time, for a maximum
of 12 weeks), irrespective of supplement allocation
group.
At both three and six months of age, triplicate mea-
surements of infant head, chest and mid-upper arm cir-
cumference were taken by field workers trained and
standardized in anthropometry to assess infant growth.
At these timepoints, in addition to infant and maternal
morbidities described above, detailed information on
breast and complementary feeding, vaccinations, possi-
ble congenital malformations, and antenatal and post-
partum care was collected.
Prematurity was defined as a live birth occurring <37
weeks gestational age calculated using the interval
between the woman’s last menstrual period and the
infant’s date of birth.
Sample Size
Restricting the number of eligible pregnancies to one
per woman, the original sample size for the JiVitA-1
trial required to detect a ≥35% reduction in all-cause
mortality in either supplement arm relative to control
was calculated to be 54,000 (18,000 per group), allowing
for a Type I error of 5%, power of 80%, equal supple-
ment allocation, design effect resulting from the rando-
mization of clusters rather than individuals of 21%
(1.21), early pregnancy loss rate of 15% (12% miscar-
riage, 3% abortion) and loss to follow-up of 10%. The
design effect used was based on measured outcomes
from our earlier trial conducted in Nepal, and was not
adjusted with data from the Bangladesh site [13]. The
calculation assumed an estimated control group mortal-
ity rate of 800 per 100,000 pregnancies. The ap r i o r i
comparisons of interests were between the placebo
group and either active arm (VA or placebo). We con-
sidered the active arms to be comparable treatment
groups, so their comparison (VA vs. beta carotene) was
n o to fi n t e r e s tf r o mad e s i g np o i n to fv i e w .B a s e do n
data collected during the first year of the trial, the sam-
ple size was increased, upon recommendation by the
trial Data Safety Monitoring Board (DSMB), to 22,580
pregnancies per group, or a total of 67,740 assuming a
re-estimated control group mortality rate of 500 per
100,000 pregnancies, a rate of pregnancy loss due to
“menstrual regulation"/induced abortion of 25%, a Type
I( a)e r r o ro f0 . 0 5 ,aT y p eI I( b)e r r o ro f0 . 2 0 ,ad e s i g n
effect of 1.21 and a revised estimate of loss to follow-up
of 2%. (Figure 2)
T h es a m p l es i z ee s t i m a t ep e rg r o u ps p e c i f i e da b o v e
was also sufficient to detect a 15-20% reduction in either
fetal loss or 3-month infant mortality, assuming control
group rates of at least 50 deaths per 1000 pregnancies
(for fetal loss) or per 1000 live births (for infant mortal-
ity), respectively, accepting the probability of an Type I
error being 0.05 and a Type II error of 0.20, respectively.
Cluster Randomization
The JiVitA-1 trial was designed as a cluster randomized
trial, thus, clusters of individuals, rather than individuals,
were randomly allocated for all consenting women of
reproductive age within a given cluster to be given one
of the three trial supplements throughout pregnancy
until the end of three months post partum. Investigators
sought to define clusters which would achieve the maxi-
mum number of clusters within the study population,
while being sufficiently large to make up a working area
for a field worker. The ‘one treatment code per field
worker’ approach also addressed concerns about the
possibility of inadvertent incorrect dosing if a single
field worker were carrying three different masked sup-
plements. Based on population density, terrain and the
expected crude pregnancy rate in the study area (~31
per 1000 population), JiVitA “sectors” of approximately
250 households each were constructed with the expecta-
tion of generating, on average, 25-30 pregnancies per
year.
In early 2001, the study area was divided into 596
smaller community groups of comparable size, with a
m e a n ± S Dn u m b e ro fh o u s e h o l d so f2 3 1±4 6i ne a c h ,
which served as units of randomization (Figure 2). To
randomize the intervention, all sectors were listed
according to their 3-digit number ranging from 001 to
596. Sectors were randomized in blocks of nine, to one
of three codes-1, 2 or 3. A block of 9 clusters was
selected to create balance of supplement allocations
within each supervisory area of 9-12 clusters. Three sets
of 3 identical coins on which the numbers 1, 2 or 3
were written were placed into a container, mixed and
removed randomly, without replacement, and the 3-digit
code of each sector was read aloud sequentially. The
code inscribed on the selected coin was assigned to that
particular sector. We engaged field supervisors directly
in the process of randomization, to increase the trans-
parency of sector allocation among workers and the
local community. Table 2 & 3 and Figures 3 & 4 display
the sector-level and geo-spatial balance achieved by the
randomization process, respectively.
Intervention Masking
Study supplements were identical in color, taste and
external appearance. Supplements were originally
shipped in identically labeled 100-count white-opaque
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2 or 3-listed on the label. Treatment codes were
assigned by the Nutrilite Health Institute and were kept
in a sealed envelope in a locked cabinet at both Nutrilite
and Johns Hopkins University. Masking was further
ensured by having a senior administrative staff (not
involved in field activities) recode the supplement bot-
tles with sector-specific permanent stickers bearing
codes from 001 to 596. Bottles were distributed, as
needed by field staff, using a controlled first-in first-out
(FIFO) system, from a temperature and humidity-con-
trolled and monitored, locked storeroom. Study partici-
pants, interviewers, field supervisors and investigators
remained masked to treatment assignments until the
end of the trial.
Supplements were released to the field, as needed, to
replenish those consumed by the study participants.
Supplement potency was regularly conducted every 6
months by independent testing laboratories and new
batches of supplements were produced every 2 to 2.5
years, depending on stock. Supplement potency results
w e r er e g u l a r l ym a d ea v a i l a b l et ot h et r i a lD S M Ba n d
ranged from 93.6% to 120.6% for beta-carotene and to
67.7 to 114% for VA.
Clinical and Biochemical Substudies
One year after the start of the main trial, a contiguous
area of 32 study clusters, balanced across treatment allo-
cations, was identified as a “Substudy Area”.A p p r o x i -
mately 600 mother-infant pairs from each treatment
group, for a total of 1800 women, representing a ~3%
sample of the overall study, were followed more inten-
sively for changes in micronutrient status in order to
document the efficacy of supplementation. This sample
was estimated to be adequate to detect expected
changes between supplemented and the placebo groups
of 8-10 μg/dl in serum retinol concentration with a
Type I error of 0.05 and a Type II error of 0.20. Con-
senting, newly pregnant women underwent additional
clinical, biochemical, body compositional, and infectious
disease protocols that included home visits during 1
st
and 3
nd trimester of pregnancy and at 3 months post-
partum. Women were measured for weight (SECA Red
Line Solar Scale, UNICEF), height (Harpenden Pocket
Stadiometer, Shorr Productions, MD, USA), mid-upper
arm circumference (adapted from the Zerfas insertion
tape) and triceps and sub-scapular skin-folds (Holtain
Ltd, UK) during the pregnancy visits. In addition,
venous blood and a vaginal swab (self-administered)
were collected and women were measured for single-fre-
quency bioelectrical impedance (RJL Systems, MI, USA)
and blood pressure. A sample of urine was also collected
and tested for sugar and/or protein content using a dip-
stick method (URiSCAN, Yeongdong Diagnostics,
Korea), after which about 10 ml of remaining urine was
banked at -20°C. Infants born to mothers in this sample
were also measured for size at birth and at 3 months of
age including weight (SECA Red Line Solar Scale, UNI-
CEF), length (Length board, Shorr Productions, MD,
USA), and head, chest and arm circumference at each
visit. At a 3 month postpartum visit, maternal anthropo-
metry was again collected (weight, MUAC and triceps
skin-fold) and breast milk, maternal (venous) and infant
(heelstick) blood was collected.
Laboratory analysis was performed at the Institute of
Nutrition, Mahidol University (Bangkok, Thailand) to
assess VA, carotenoid, and vitamin E concentrations in
plasma and breastmilk. Ferritin and other nutritional
assays in plasma were performed at the micronutrient
laboratory at the Center for Human Nutrition (Johns
Hopkins Bloomberg School of Public Health, Baltimore,
MD, USA). Hemoglobin levels were measured at the
time of each blood draw with a Hemocue hemoglobin-
ometer (Hemocue, Inc., Mission Viejo, CA). Severely
anemic women (Hb < 7 g/dl) were treated with 120 mg
iron and 400 μg folate supplements for 3 months fol-
lowing WHO guidelines.
A birth defect surveillance system was established to
monitor levels of visible birth malformations in each of
the three study arms. Trained field workers conducted a
complete external visual examination of all infants at
their 3-month visit, noting any anomalies or deviations
from normal, erring on the side of increased sensitivity
and lower specificity. These anomalies were then
checked by either a paramedic or physician, who
Table 2 Sector-Level Characteristics, by treatment group
Presence in Sector Placebo
N = 198
Vitamin A
N = 198
b-Carotene
N = 200
n%n n n %
Market Structures
Permanent market ** 15 7.6 40 40 28 14.1
Regular (weekly) market 15 7.6 19 19 10 5.1
Rice Mill * 112 56.6 134 134 107 54.0
Education
Primary School 83 41.9 93 93 95 48.0
High School * 15 7.6 33 33 30 15.2
Health Services
Private Doctor (MBBS) 2 1.0 6 6 6 3.0
Family Welfare Clinic * 6 3.0 16 16 7 3.5
Medicine Shop 39 19.7 57 57 50 25.2
Village Doctor 89 45.0 94 94 107 54.0
Infrastructure
Year Round Finished Road 62 31.3 48 48 53 26.8
Electricity 99 50.0 103 103 94 47.5
* Significant differences between treatment groups, p-value <0.05
** Significant differences between treatment groups, p-value <0.01
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Page 8 of 17performed a thorough examination of the child, docu-
menting any anomaly with high-resolution digital photo-
graphy. Photographs, maintained in a large image
database, and examiner’s notes were archived for future
review by an expert teratologist to diagnose and classify
any birth defects. Children identified with cleft lip and/
or palate defects were offered free surgical correction
through a local humanitarian organization.
Ethical Approval
The study protocol was reviewed and approved by the
Johns Hopkins Bloomberg School of Public Health Insti-
tutional Review Board (IRB) and the Bangladesh Medical
Research Council (BMRC). Both institutional review
boards periodically (annually, in the case of the Johns
Hopkins IRB) reviewed the progress of the trial, word-
ing, content and use of informed consent and assent
procedures. The informed consent process included,
when so desired by the subjects, husbands, in-laws and
sometimes community members. Ultimately, individual
consent was sought from the participating women and
documented.
A Data Safety and Monitoring Board (DSMB) was
formed to examine, over the course of the trial, its
proper implementation and to monitor the safety and
efficacy of interventions being tested. It included a total
of 5 experts from Bangladesh (n = 2), the US (n = 2),
and the United Kingdom (n = 1) with training and rele-
vant expertise in reproductive health, public health
nutrition, epidemiology, obstetrics and gynecology and
Table 3 Household Socioeconomic Characteristics at Enrollment, by treatment group
1
Baseline Socioeconomic Characteristics PL
N = 19,862
VA
N = 19,806
BC
N = 19,998
n%n%n%
Literacy
Read/write (self) 8473 42.7 8308 42.0 8451 42.3
Read/write (husband) 9079 45.9 8969 45.5 9026 45.4
Woman’s Education
Class 1 to Class 9 8469 42.7 8382 42.4 8445 42.4
Class 10 complete (SSC) 604 3.0 535 2.7 618 3.1
Class 11+ 756 3.8 745 3.8 790 4.0
Husband’s Education
Class 1 to Class 9 6063 32.0 5969 31.6 5934 31.2
Class 10 complete (SSC) 863 4.6 819 4.3 845 4.4
Class 11+ 1733 9.1 1760 9.3 1826 9.6
Husband’s Occupation
Farmer 5739 28.9 5662 28.6 5711 28.6
Laborer 5026 25.4 5025 25.4 5020 25.2
Fisherman 148 0.8 129 0.7 182 0.9
Contracted laborer 215 1.1 201 1.0 209 1.0
Business 6704 33.8 6747 34.1 6862 34.4
Private 1403 7.1 1438 7.3 1386 6.9
Government service 286 1.4 263 1.3 277 1.4
Other 304 1.5 301 1.5 310 1.6
Religion*
Islam 18374 92.7 18404 93.1 18205 91.2
Hindu 1425 7.2 1350 6.8 1691 8.5
Other 25 0.1 20 0.1 64 0.3
Household Assets
Own Cattle 7944 40.1 7822 39.6 7936 39.8
Own Goats/Sheep 4456 22.5 4500 22.8 4427 22.2
Own Bicycle 7486 37.8 7487 37.9 7491 37.5
Own Land 16462 83.5 16460 83.6 16438 82.9
Own Irrigation Pumps 2031 10.2 2039 10.3 2097 10.5
Have Electricity 2372 12.0 2469 12.5 2513 12.6
1Missing numbers (maximum number missing) 886, 917 and 963 for group PL, VA and BC, respectively.
* Significant differences between groups, p-value <0.001
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Page 9 of 17biostatistics. The DSMB met four times throughout the
study, when ~30%, ~55%, 70% and 85% of the planned
sample size had been reached, to assess methodological
adherence to the study protocol, quality control of data
collection, compliance of enrolled women with supple-
ment receipt, steps to protect human subjects, and evi-
dence of benefit or harm. The JiVitA-1 study was
registered with ClinicalTrials.gov as trial number ID
GHS-A-00-03-00019-00.
Results
Major Field Procedures
Initial Census
From July-August 2001 a staff of 596 local female work-
ers carried out a door-to-door census of every house-
hold in the study area to identify all women eligible to
contribute a pregnancy to the trial. Women of repro-
ductive age living with their husbands were listed on a
roster that included the unique address of their house
(Sector + household number) and a unique single digit
number to distinguish multiple women in one house-
hold. This list was computerized and used to identify
pregnant women during subsequent 5-weekly pregnancy
surveillance rounds. Amenorrheic women who were
either pregnant or breast feeding an infant under
12 months of age at the time of the initial census were
placed on a “Waiting List” until they resumed menstrua-
tion or their infant turned 12 months of age, whereupon
they were placed onto the pregnancy surveillance roster.
(See Figure 5.) The schedule of surveillance, interviews
and consent interactions are described below, and sum-
marized in Table 4.
At the outset, the surveillance roster contained the
names of 102,771 women. The list was continuously
updated as eligible, newly-married women became
resident in the study area, as described earlier. Every
25 weeks, a list of women eligible for pregnancy surveil-
lance, stratified by study sector, was printed and pro-
vided to field workers as a roster to visit women and
screen for incident pregnancy.
ȕ-Carotene (n=200) 
Placebo   (n=198) 
Vitamin A  (n=198) 
Figure 3 Study area map illustrating the randomized distribution of treatment allocation to study sectors.
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The field trial formally began on August 12, 2001 with
the initiation of pregnancy surveillance for the purpose
of identifying and enrolling pregnant women into the
trial. Using the roster, a team of nearly 600 field staff
was responsible to perform pregnancy ascertainment
every five weeks by asking women about the occurrence
of their menstrual period in the previous month and
offering a urine-based pregnancy test to those who
reported not having menstruated.
Enrollment, Supplementation and Follow-up of Pregnant
Women
Women with a positive pregnancy test were visited, typi-
cally within a week of the test, by a supervisor (team
leader) who explained details of trial participation in a
standardized fashion and sought consent to participate
in the weekly supplementation trial and periodic home
interviews. Irrespective of consent, all women were pro-
vided with a color graphical pamphlet entitled “Advice
for Pregnant Women”,d e s i g n e db yt h eO b s t e t r i ca n d
Gynecologic Society, Bangladesh (OGSB), along with a
maternal and infant immunization schedule. Consenting
women were interviewed soon after by a trained field
interviewer to obtain a pregnancy history, socioeco-
nomic data, information about recent (past 7 and 30
day) morbidity symptoms, dietary and alcohol intake,
tobacco product use and household chores performed in
the previous week. At this time, maternal nutritional
status was also assessed by measuring mid-upper arm
circumference. Consenting women continued to be vis-
ited each week by local female supplement distributors
during pregnancy through 12 weeks postpartum and
given a coded capsule under staff supervision.
Night blindness assessment and treatment
At 28 weeks of gestation, following a pre-printed, sec-
tor-specific, ‘night blindness assessment roster’,F D s
inquired about night blindness using an identified local
term (“ratkana/aloandari”). Positive respondents were
revisited within a week by a trained field interviewer
who gathered additional symptoms to confirm the
Figure 4 GIS maps of the JiVitA-1 study area, illustrating successful sector-level randomization by displaying sector means of four
select characteristics of enrolled women in those sectors (early pregnancy arm circumference, living standards index [14], gestational
age at first dose, and dosing compliance throughout the duration of the study).
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Page 11 of 17diagnosis. “Confirmed” cases were offered the WHO-
recommended treatment for night blindness in preg-
nancy (25,000 IU VA every week for 4 weeks); if symp-
toms failed to resolve, subjects were provided 4
additional weeks of VA therapy, up to a maximum of 12
weeks of supplementation.
Infant registration
Live born infants were registered by the field distribu-
tors usually within a week of birth, during their routine
supplementation visits to homes.
Three month post partum interview
A trained field interviewer returned to the home of par-
ticipating women 12 weeks after the pregnancy out-
come, irrespective of the type of outcome, and
interviewed women to obtain (a) maternal re-consent
for interview procedures, (b) maternal histories of ill-
nesses during and following pregnancy, including
detailed histories during the puerperal period (c) his-
tories of infant breast and complementary feeding prac-
tices and morbidity symptoms, (d) to assess infant
growth by circumferential measurements, and (e) to
identify gross physical deformities by visual inspection.
As described earlier, perceived physical abnormalities
prompted a later visit and clinical examination by a
trained research physician or paramedic, which included
digital photography for future expert review. Histories of
gross abnormalities for deceased infants were obtained
by a verbal autopsy interview.
Cessation of maternal supplementation
At 12 weeks postpartum, participating mothers ceased
being visited at home and supplemented on a weekly
basis. Each study participant was eligible to contribute a
single pregnancy to the JiVitA-1 trial. Each household
continued to be visited, however, even after cessation of
supplementation, on a five-weekly basis for the purposes
of identifying any newly married women entering the
study area.
Six-month post partum interview
Participating mothers were revisited and interviewed
again to obtain histories of morbidity, diet, activity,
infant feeding and morbidity, and to assess infant
growth, employing the same procedures performed at
the 3-month visit. Verbal autopsies were conducted for
deceased infants.
Cause of Death Investigation (Maternal and Infant Verbal
Autopsy)
Within 1 to 2 months following the death of an enrolled
woman, a home visit was conducted by a trained inter-
viewer to elicit a history of morbidity and other events
that occurred or conditions that existed in the weeks
leading up to death. Data collected from these “verbal
autopsies” were independently reviewed by two physi-
cian reviewers (always including one obstetrician/gyne-
cologist and one generalist), and a direct and underlying
cause of death was assigned. Following the independent
review, a joint consensus was reached on the most likely
direct and underlying causes of death for each case.
Infant Verbal Autopsies were conducted soon after the
infant’s death, by a trained non-medical interviewer.
Each infant “verbal autopsy” was independently reviewed
by a team of two trained Research Physicians, and a
consensus on the direct and underlying cause of death
reached through discussion. When consensus could not
be reached, a third independent review was performed.
Quality Control
Activities to ensure high-quality and standardized inter-
view and measurement procedures included a rigorous
recruitment process to select and hire qualified persons
demonstrating aptitude for field work, provision of
extensive training, certification of interviewers through
standardization exercises, weekly supervisory visits of
field activities by a two-tiered quality control system, a
weekly peer-review of completed forms, outlier analysis
and investigation of frequency distributions for ques-
tionnaire responses and anthropometric measurements,
Figure 5 Flow diagram of main JiVitA-1 trial procedures.
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Page 12 of 17and random re-interviews conducted by a six-member
quality control unit. Interviewers were also directly
observed, and participants were visited randomly to
evaluate the quality of the interaction with the inter-
viewer. A computer-controlled roster was used to track
field area visits and specific staff member visits to
ensure all areas and staff were supervised with compar-
able intensity over the course of the trial. Regular qual-
ity control of all anthropometric instruments was
performed, ranging from calibration of all equipment
(scales, calipers, and stadiometers) on a daily basis, to a
systematic, study-wide instrument calibration every
three months.
Study Management
A series of weekly meetings were held every week at dif-
ferent levels of the field staff hierarchy which served as
an information conduit between the field workers, field
supervisors, and study managers up to the project inves-
tigators. Every Thursday, each team of field distributors
(described earlier) met with their respective Team Lea-
ders, who prepared a consolidated report of new preg-
nancies, pregnancy outcomes, and in-migrating, eligible
married women of reproductive age. Any field problems,
logistic needs, or procedural issues were raised and
addressed at this meeting. Every Sunday morning, four
Team Leaders met with their Area Coordinator, to con-
vey their area’s performance, review any new protocols
or procedural changes and to exchange any data des-
tined for the Data Management Center (DMC). On Sun-
day evenings, all the Area Coordinators (n = 14)
converged at the project field headquarters for a full
weekly debrief and interaction with the project manage-
ment team, including scientific, logistic, financial, and
administrative officers. Thus, on a weekly basis, a cycle
of consecutive meetings served as an effective channel
for primary data to flow from the field to the DMC
(and vice versa), but also for information to flow, in
both directions, to and from each one of over 850 field
and project staff.
Data Flow and Management
The data management system for the study included
customized procedures covering a range of essential
activities from tracking the transmittal of data from the
Table 4 Schedule of surveillance, interviews and consent interactions in the main JiVitA-1 trial
Survey/Questionnaire Scheduled at Contents Conducted
by *
Consent/
Reconsent
Women’s Enrollment Survey Beginning of trial Baseline census of all women of reproductive age, enrollment
into surveillance
FD Y
Newly Married Woman Survey Ongoing, 5-
weekly
Allows enrollment of eligible, newly married women FD Y
Pregnancy Surveillance Survey Ongoing, 5-
weekly
Urinary hCG-based identification of new pregnancies FD Y, for urine
test
Women’s Consent
Interview
Pregnancy
identification
Informing women about the trial, obtaining consent for
interviews and supplementation
TL Y
Pregnancy Dosing Visits Weekly Weekly supplementation of enrolled pregnant women FD N
Pregnancy Enrollment
Questionnaire
First week after
consent
Baseline characteristics, pregnancy history, 7 d diet, 7 d/30 d
morbidity, exposures
FI N
Socioeconomic Status
Questionnaire
First week after
consent
Education, employment of self and husband, household assets FI N
Family History Questionnaire First week after
consent
Parental vital status, cause of death, chronic morbidity FI N
Late Pregnancy Questionnaire At 28 weeks
gestation
7 d diet, 7 d/30 d morbidity, exposures FI N
Three-Month Postpartum
Questionnaire
At 12 weeks
postpartum
Complications of labor and delivery, 7 d diet, 7 d/30 d morbidity,
exposures
FI N
Six-Month Postpartum
Questionnaire
At 24 weeks
postpartum
7 d diet, 7 d/30 d morbidity, exposures FI N
Miscarriage/Stillbirth
Questionnaire
4 weeks after
event
Complications of labor and delivery, care-seeking FI Y
Verbal Autopsy - Infant 4 weeks after
event
Enhanced from WHO standard instrument FI Y
Verbal Autopsy - Mother 4 weeks after
event
Enhanced from WHO standard instrument RP Y
* FD = Field Distributor, must be local resident with minimum education level of 8
th grade TL = Team Leader, must be local resident with a minimum of a
college degree
FI = Field Interviewer, must be local resident with a minimum of a college degree
RP = Research Physician, minimum MBBS-degree, with specific verbal autopsy training
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Page 13 of 17field to the DMC, the entry and quality control of com-
pleted forms, the querying (where possible) of missing
or invalid data, to the archiving of physical forms. Once
collected, the data were reviewed and corrected, if
necessary, at the field level, and forms packaged,
grouped by type, into waterproof data folders, enumer-
ated on a transmittal list by a supervisor, and sent to
the DMC by project vehicle in locked data trunks every
week. The transmittal list was checked upon arrival at
the DMC against forms received and were then assigned
to data entry operators (n = 12) for data entry. Missing
forms could thus be immediately sought and recovered
from the field with the help of the field supervisors.
Data entry was performed on networked PCs using
Microsoft SQL Server (v8.0, Microsoft
®,S e a t t l e ,W A ,
USA) as the relational database engine. The relational
database was designed to maximize data efficiency and
minimize database size through limited data redun-
dancy. Data entry screens were custom-designed using
Active Server Pages (ASP, Microsoft
®, Seattle, WA,
USA), which mimicked the paper forms through an
HTML interface. Javascript code validated the entered
data using standard range, consistency and logical
checks within fields; logical consistency across multiple
forms received for a particular participant was ensured
via server-side checks against the SQL database.
Critical data such as identifiers were always entered
twice. To quantify error rates by form, worker, and over
time, and to further reduce data entry errors, each week
a purposeful sample of forms was re-entered by a differ-
ent data entry operator. A script flagged any discrepan-
cies between the two entries; conflicts were investigated
and resolved by a data supervisor. Individual data entry
operator performance was tracked and specialized
supervision, re-entry, or retraining was conducted as
necessary. Data entry operators were also evaluated and
trained in ergonomic positioning and required to take
10-minute breaks each hour to prevent eyestrain. An
overall average error rate of less than 3 per 10,000 key-
strokes was calculated for the JiVitA data entry team
over the course of the study.
Problems identified during data entry or in data clean-
ing were logged for supervisor assessment. Some pro-
blems were resolved by review of the source data or of
other related forms. Other problems requiring additional
data from the field were assigned unique error numbers,
described in detail on a printed form and sent to the
appropriate field supervisor for investigation and resolu-
tion. Field queries were returned within an average of 2
weeks, and were actively managed in a query resolution
database. Once resolved to the satisfaction of the Data
Supervisor, the data was corrected on the source form
and edited in the database. Although from the begin-
ning, all modifications and corrections to the database
were documented and archived systematically, from
March 2003, a complete electronic record of every
change to the database after initial data entry (including
the time and person making the change) was preserved
to prevent any undocumented data manipulation or
erroneous data modification. The ongoing checking of
the database helped improve the data quality by provid-
ing timely feedback and turn-around of error correction,
and allowed for a more timely analysis at the end of the
study.
Data were initially backed up daily onto rewriteable
C D - R O M s ,w h i c hw e r ee v e n t u a l l yr e p l a c e db yp o r t a b l e
external hard-drives. These were stored off-site in a
locked, secure cabinet. An encrypted copy of the data-
base was also uploaded to Johns Hopkins initially on a
monthly basis, and as internet connectivity improved,
on a weekly basis using a connection authenticated via
RSA and encrypted using Advanced Encryption Stan-
dards (AES) over a Secure Sockets Layer (SSL) connec-
tion. The data entry terminal network was at all times
isolated from the office network with internet access to
eliminate any data security risks.
Discussion
The conduct of large, population-based trials in remote,
resource-poor settings represents substantial challenges
to maintaining scientific integrity. The number of
enrolled subjects needed to demonstrate impact on a
rare event such as mortality (even in high risk areas)
usually requires a sizeable population catchment area
and a large and multifaceted team of field workers,
supervisors, and technical, administrative and logistics
support staff. It is often best to select workers by com-
munity transparent methods that identify skills and apti-
tude, though such staff usually arrive with little prior
research experience. In JiVitA-1, detailed training and
standardization protocols were developed to train cadres
of field and support staff, including community surveil-
lance workers, interviewers and supervisors, manage-
ment, accounting, inventory and logistics staff. The
layout and organization of field offices was carefully
defined, from specific guidance on weekly meeting man-
agement and documentation, to the physical location of
supplements, forms and other materiel. This enabled
supervisors and workers to substitute for each other, as
needed, across the large area, in case of medical or
other leave. Another focus of JiVitA staff training was
the standardization of handwritten English numbers (0-
9) and letters (A-Z) that facilitated data entry and
reduced error rates in data recording, coding and entry.
We documented training curricula and required compe-
tencies for each level of worker that enabled consistency
in performance over time, especially in the presence of
occasional worker turnover.
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the local culture and adopting appropriate approaches
to obtaining informed consent are essential to fulfill
ethical obligations to inform and assure volunteer invol-
vement. Consent processes were adapted to the context,
by engaging, as appropriate, the household heads, hus-
bands, and mothers-in-law. Our procedures had to
allow for an extended consent period as women often
requested the opportunity to discuss their participation
with their families prior to consent.
In this conservative, traditional and rural population, a
number of strategies were adopted to reach, inform and
communicate with our target, female and often pregnant
and lactating audience - including the employment of a
largely local, female workforce (>90% of our 850 staff),
active engagement of the regional and local community
leadership, and a good neighbor policy that involved
assisting district communities, especially in times of
emergency [8]. Advocacy and continuing education
meetings engaged the formal and informal medical com-
munities, the local government and health system, as
well as grassroots NGO constituencies working in the
area.
Most study activities depended on strictly prescribed
information flow and activity ‘cycles’,r a n g i n gf r o mt h e
weekly supervisor-field worker meetings, to the regular,
field-wide, quality control rounds. The cyclic flow of
data from the field to the data management system, and
the return of new information, instructions and queries
back to the field in the form of pre-printed ‘smart’ ros-
ters or forms allowed for increased efficiency and
decreased opportunity for error by reducing handwriting
and coding in the field. For example, by pre-filling the
“End of Supplementation” boxes on supplementation
rosters, we avoided worker calculation errors. We
employed modern, but inexpensive barcoding to ‘iden-
tify’ pre-printed roster pages; when these pages returned
with hand-written data, their entry was expedited signif-
i c a n t l yb yas i m p l eb a r c o d escan. Preprinted data was
r e c a l l e df r o mad a t a b a s ea n du s e dt op o p u l a t ec r i t i c a l
identifier, name and location fields - in under one sec-
ond, compared to 3-5 minutes required to double-enter
the same data.
Innovations in worker performance monitoring were
facilitated by relatively easy access to data in modern
relational databases. Data entry operators were individu-
ally graded on a monthly basis, based on entry rate,
form-specific error frequency, and query generation.
Field-based errors were documented in the database and
used to provide feedback to field supervisors, by fre-
quency of error, but without worker identifiers linked to
specific faults (e.g., digit preferences in continuous mea-
sures) to avoid subsequent overcorrection and resultant
biases in subsequent data collection by outlier staff.
Using data-driven report software, we created ‘anthropo-
metry report cards’ as quality control tools for supervi-
sors to identify possible data falsification or procedural
inconsistencies. These report cards calculated, over a
specified period, measures of digit preference (unexpect-
edly high rates of certain terminal digits in anthropo-
metric measurements, such as X.0 or X.5), rates of three
identical measurements when taken in triplicate, and
comparisons of individual median values, compared to
global (all interviewer) medians.
Besides the primary study database, secondary man-
agement databases were created to systematize processes
ranging from supplement and field logistic distribution
to community and local health system advocacy con-
tacts. The latter ensured frequent and regular courtesy
visits to private and government doctors located across
the study site, to address any concerns and to maintain
a sense of community ownership of the ongoing trial.
Each supervisory visit to one of 56 field managers was
logged in a ‘lightning strike’ database, to fairly distribute
unannounced quality control visits across the 435 sq.
km. study area. This also served as a mechanism to
monitor the supervisors themselves.
The weekly cycle of data transfer, supervisory meet-
ings, and investigator feedback throughout the course of
this trial allowed for rapid responses to queries from
field workers, timely community management, and cor-
rection of data errors with minimum delay. At the field
level, these cycles were introduced into every participat-
ing household through the provision of project-printed
annual calendars. Workers marked their visits on these
calendars, hung in a prominent place in each village
home. Participants were encouraged to mark discretely
the start date of their menstrual cycles on the calendar,
further improving the recall of last menstrual period
(LMP, for gestational age calculation) and outcome
dates. These calendars were also used as supervisory
tools as they documented the date and frequency of sur-
veillance worker visits.
Finally, we continually explored novel applications of
GIS and GPS technologies to enhance field operations
beyond the core function of identifying and following
study participants over time. As shown in Figure 4, the
display and geospatial analysis of cluster-level data
allowed us to demonstrate spatial balance in randomiza-
tion, as well as identify real geographic differences
within a fairly homogenous population (e.g. an east-west
mid-upper arm circumference gradient; a socio-eco-
nomic status gradient from northwest to southeast).
This understanding of spatial variance is important in
understanding possible inter-worker variability in
anthropometric and socioeconomic data, even within a
fairly homogenous rural setting. We also used real-time
geographic plotting of refusals to Substudy activities (e.
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wide weekly rates of unmet subjects to identify unantici-
pated community reactions or poor worker perfor-
mance, respectively. This permitted rapid, proactive
early responses to these situations. Equipping field phy-
sicians with relatively inexpensive handheld GPS units,
updated with the locations of scheduled interview
households, increased their weekly work productivity
significantly; an analysis of verbal autopsies conducted
in the weeks prior to and following the introduction of
GPSs revealed a 20% increase in weekly performance of
these limited, highly trained project staff.
Conclusion
In addition to the core research methods of the JiVitA-1
trial, these examples illustrate context-specific proce-
dures, modifiable for other applications, that were devel-
oped to implement and manage a large community-
based maternal supplementation trial. Their principal
aim was to improve efficiency, quality and scientific
validity of human subject contact and data collection
during the trial. Continuous emphasis on innovation,
especially adaptation of new technologies, while strin-
gently adhering to accepted principles of trial conduct,
can drive community-based research at scale to be cost-
effective, time-appropriate and efficient. Low levels of
resource represent challenges to overcome, but never
excuses for failing, to achieve scientific rigor and cred-
ibility. The resonance of this northern, rural Gaibandha
and Rangpur site with rural Bangladesh, and population
settings across Gangetic South Asia, may help to pro-
mote uptake and application of findings from this and
future JiVitA trials.
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